Table 1 Patients’ characteristics
Variables | |
|---|---|
Median age, years (range) | 71.2 (52.5–82.9) |
Cycles of docetaxel, cycles (range) | 9 (1–55) |
Use of enzalutamide, n (%) | 35 (72.9) |
Use of abiraterone acetate, n (%) | 26 (54.1) |
Median aBSI, %, (range) | 3.5 (0.0–12.9) |
Median baseline PSA, ng/mL (range) | 152.1 (1.6–3564.0) |
Median baseline Hb, g/dL (range) | 11.0 (8.1–14.2) |
Median baseline LDH, IU/L (range) | 262 (124–3509) |
Median baseline ALP, IU/L (range) | 414 (111–3653) |
Lymph node metastasis, n (%) | 32 (66.6) |
Visceral metastasis, n (%) | 23 (47.9) |
Cycles of cabazitaxel, cycles (range) | 4 (1–15) |
Median observation period, months (range) | 7.2 (0.6–25.0) |
Cancer death, n (%) | 25 (56.2) |